Vorapaxar sulfate

Vorapaxar sulfate is a thrombin receptor antagonist used in the treatment of thrombosis. It is marketed under the brand name Zontivity by Merck & Co..

Pharmacology[edit | edit source]

Vorapaxar sulfate works by inhibiting the action of thrombin, a protein involved in blood clotting. It specifically targets the protease-activated receptor 1 (PAR-1), which is a thrombin receptor found on platelets. By blocking this receptor, vorapaxar sulfate prevents thrombin from activating platelets and initiating the clotting process.

Clinical Use[edit | edit source]

Vorapaxar sulfate is used to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or with peripheral arterial disease (PAD). It is usually given in combination with aspirin or clopidogrel.

Side Effects[edit | edit source]

The most common side effects of vorapaxar sulfate include bleeding and bruising. Serious side effects may include severe bleeding, anemia, and thrombocytopenia.

Contraindications[edit | edit source]

Vorapaxar sulfate is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage. It is also contraindicated in patients with active pathological bleeding.

Drug Interactions[edit | edit source]

Vorapaxar sulfate may interact with other anticoagulants, increasing the risk of bleeding. It may also interact with certain types of antidepressants, increasing the risk of serotonin syndrome.